GlassScriptPhysician profile
David Robert Brooker
NPI 1649214552
$20,654.85
in general payments reported to CMS, 2019-2025
25 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $913 · 2021: $870 · 2022: $8,014 · 2023: $5,227 · 2024: $4,134 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,519 · Food and Beverage: $2,924 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,519.00 |
| Food and Beverage | $2,923.58 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $6,407.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,482.34 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $3,028.40 | 2019-2025 | Jynarque, Voyxact |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,928.18 | 2023 | |
| Horizon Therapeutics Plc | $1,084.75 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $780.73 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $749.63 | 2019-2024 | Rayaldee |
| Vifor Pharma, INC. | $438.04 | 2019-2022 | |
| Amgen INC. | $335.24 | 2022-2024 | Tavneos, Parsabiv, Repatha |
| Akebia Therapeutics INC | $324.12 | 2019-2024 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $265.06 | 2019-2023 | Korsuva, Velphoro |
| Glaxosmithkline, LLC. | $180.68 | 2022-2024 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $149.32 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.11 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $54.93 | 2024 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rockwell Medical, INC. | $54.62 | 2020 | |
| Ardelyx, INC. | $53.65 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $45.91 | 2019 | |
| Aurinia Pharma U.S., INC. | $45.35 | 2022-2023 | Lupkynis |
| Daiichi Sankyo INC. | $37.23 | 2021 | |
| Mallinckrodt Hospital Products INC. | $22.99 | 2022 | |
| Baxter Healthcare | $21.24 | 2023 | Renal - Amia |
| Novo Nordisk INC | $20.35 | 2025 | Ozempic |
| Angiodynamics, INC. | $16.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.